Overview We are a clinical stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF , and our site-specific conjugation platform, XpressCF+ . We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, and dual-payload ADCs, or dpADCs. Our molecules are directed primarily aga...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001193125-26-119873 | EDGAR | 106K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038884 | EDGAR | — |
| 2024-03-25 | 2023-12-31 | 0000950170-24-035949 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000950170-23-010976 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002312 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001564590-21-013945 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-010890 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001564590-19-010253 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-270036 | EDGAR | 71K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105219 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067072 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126407 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096336 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058718 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-063037 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041416 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021976 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023279 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015584 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008531 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-23 | 0001193125-26-119844 | EDGAR | 3K words |
| 2026-02-10 | 0001193125-26-044934 | EDGAR | — |
| 2025-12-17 | 0001193125-25-322859 | EDGAR | — |
| 2025-12-03 | 0001193125-25-306786 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269833 | EDGAR | — |
| 2025-09-29 | 0001193125-25-223434 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105159 | EDGAR | — |
| 2025-06-25 | 0000950170-25-089978 | EDGAR | — |
| 2025-06-10 | 0001193125-25-138481 | EDGAR | — |
| 2025-06-02 | 0001193125-25-133268 | EDGAR | — |
140 total filings indexed. 110 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001382101 |
| Ticker | STRO |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.sutrobio.com |
| Listed | 2018-09-27 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report